Table 3.
CVD Mortality among Non-aTRH NHANES (1988–1994 and 1999–2010) Participants
| Unweighteda | Weightedb | Crude IR (Weighted) | Model 1: Unadjustedc | Model 2d | Model 3e | Model 4: Fully Adjustedf | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N (%) | Deaths (%) | N in millions (%) | Deaths in millions (%) | Per 1000 PY | HR | p | HR | p | HR | p | HR | p | |
| Non-aTRH < 3 medications | 3837 (60.4) | 243 (6.3) | 23.49 (64.1) | 1.14 (4.9) | 6.3 (5.4, 7.5) | Reference | Reference | Reference | Reference | ||||
| Non-aTRH 3 medications |
998 (15.7) | 96 (9.6) | 5.55 (15.1) | 0.46 (8.3) | 13 (9.9, 16.9) | 2.14 (1.55, 2.95) | < 0.001 | 1.59 (1.18, 2.16) | 0.003 | 1.57 (1.15, 2.15) | 0.005 | 1.35 (0.98, 1.86) | 0.064 |
Abbreviations: aTRH apparent treatment-resistant hypertension, IR incidence ratio
a Unweighted refers to the actual number (%) of the NHANES participants from the final cohort
b Weighted refers to the projected numbers in the US populations and accounts for NHANES design and sampling weights
HR from Cox proportional hazards models with adjustment as follows:
cModel 1 was unadjusted
dModel 2 adjusted for age, sex and race
eModel 3 adjusted for variables in Model 2 + body mass index (spline at 18 kg/m2 and 25 kg/m2), history of diabetes and cardiovascular disease, smoking status, serum total cholesterol, and ln-C-reactive protein (natural log transformed)
fModel 4 adjusted for variables in Model 3 + eGFR CKD EPI (spline at 60 and 90) and ln-ACR